RCUS (STOCKS)
Arcus Biosciences, Inc.
$28.860000
-0.100000 (-0.35%)
Prev close: $28.960000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Terry J. Rosen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,850.46M
- Employees
- 674
- P/E (TTM)
- -7.42
- P/B (TTM)
- 7.93
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
10
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.72 | $-0.92 | +0.1962 | +21.41% |
|
Mar 2026 (Q1)
|
$-1.02 | $-0.89 | -0.1256 | -14.04% |
|
Dec 2025 (Q4)
|
$-0.89 | $-1.05 | +0.1567 | +14.97% |
|
Sep 2025 (Q3)
|
$-1.27 | $-1.34 | +0.0662 | +4.95% |
Financial Statements
| Revenues | $117.00M |
| Benefits Costs and Expenses | $577.00M |
| Costs And Expenses | $577.00M |
| Nonoperating Income/Loss | $26.00M |
| Operating Expenses | $603.00M |
| Depreciation and Amortization | $10.00M |
| Research and Development | $497.00M |
| Other Operating Expenses | $98.00M |
| Operating Income/Loss | -$486.00M |
| Income/Loss From Continuing Operations After Tax | -$460.00M |
| Income/Loss From Continuing Operations Before Tax | -$460.00M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$460.00M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$460.00M |
| Net Income/Loss Available To Common Stockholders, Basic | -$460.00M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$3.91 |
| Diluted Earnings Per Share | -$3.91 |
| Basic Average Shares | 235,900,000 |
| Diluted Average Shares | 361,700,000 |
| Assets | $924.00M |
| Current Assets | $756.00M |
| Noncurrent Assets | $168.00M |
| Fixed Assets | $36.00M |
| Other Non-current Assets | $132.00M |
| Liabilities | $460.00M |
| Current Liabilities | $198.00M |
| Accounts Payable | $34.00M |
| Wages | $21.00M |
| Other Current Liabilities | $143.00M |
| Noncurrent Liabilities | $262.00M |
| Long-term Debt | $101.00M |
| Other Non-current Liabilities | $161.00M |
| Equity | $464.00M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $464.00M |
| Liabilities And Equity | $924.00M |
| Net Cash Flow From Operating Activities | -$474.00M |
| Net Cash Flow From Operating Activities, Continuing | -$474.00M |
| Net Cash Flow From Investing Activities | $63.00M |
| Net Cash Flow From Investing Activities, Continuing | $63.00M |
| Net Cash Flow From Financing Activities | $313.00M |
| Net Cash Flow From Financing Activities, Continuing | $313.00M |
| Net Cash Flow | -$98.00M |
| Net Cash Flow, Continuing | -$98.00M |
| Comprehensive Income/Loss | -$461.00M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$461.00M |
| Other Comprehensive Income/Loss | -$136.00M |
| Other Comprehensive Income/Loss Attributable To Parent | -$1.00M |